CD1A and melanoma: Interestingly, the administration CpG B-type ODN PF-3512676 (also known as CpG 7909) as immunostimulatory adjuvant therapy in stage I-III melanomas enhanced the activation of pDCs and CD1a+ mDCs, and lowered the frequency of immunosuppressive Treg, reducing the risk of metastatic spread in early-stage melanomas.